High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls

Haematologica

Volumn 92, Issue 3, 2007, Pages 357-365

  Quiroga, Teresa ^a   Goycoolea, Manuela ^a   Panes, Olga ^a   Aranda, Eduardo ^a   Martínez, Carlos ^a   Belmont, Sabine ^a   Muñoz, Blanca ^a   Zúñiga, Pamela ^a   Pereira, Jaime ^a   Mezzano, Diego ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Bleeding of unknown cause; Diagnosis of inherited disorders of primary hemostasis; Mild bleeding disorders; Mucous and skin bleeding; Platelet function study; Relative frequency of disorders of primary hemostasis

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING DISORDER; CAUSAL ATTRIBUTION; CHILD; CLINICAL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; PHYSICIAN; PREVALENCE; PROSPECTIVE STUDY; REFERENCE VALUE; SCORING SYSTEM; THROMBOCYTE ANOMALY; THROMBOCYTE FUNCTION; VON WILLEBRAND DISEASE; ANAMNESIS; BLEEDING DISORDER; BLOOD; BLOOD CLOTTING PARAMETERS; CASE CONTROL STUDY; CASE MANAGEMENT; CLASSIFICATION; DRUG EFFECT; FEMALE; GENETICS; HOSPITALIZATION; INSTRUMENTATION; MALE; METHODOLOGY; MIDDLE AGED; MUCOSA; PHENOTYPE; PREDICTION AND FORECASTING; PRESCHOOL CHILD; QUESTIONNAIRE; SECRETION; SIGNAL TRANSDUCTION; SKIN DISEASE; SPAIN; THROMBOCYTE; THROMBOCYTE DISORDER;

ADRENALIN; HEMOGLOBIN; SEROTONIN;

ADOLESCENT; ADULT; BLEEDING TIME; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; CASE MANAGEMENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COAGULATION PROTEIN DISORDERS; EPINEPHRINE; FEMALE; HEMOGLOBINS; HEMORRHAGE; HEMORRHAGIC DISORDERS; HUMANS; MALE; MEDICAL HISTORY TAKING; MIDDLE AGED; MUCOUS MEMBRANE; PHENOTYPE; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEROTONIN; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SKIN DISEASES; SPAIN; VON WILLEBRAND DISEASE;

EID: 34247606049     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10816     Document Type: Article

References (41)

1. Mauser Bunschoten EP, van Houwelingen JC, Sjamsoedin Visser EJM, van Dijken PJ, Kok AJ, Sixma JJ. Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost 1988; 59:349-52.
2. Nosek-Cenkowska B, Cheang MS, Pizzi NJ, Israels ED, Gerrard JM. Bleeding/bruising symptomatology in children with and without bleeding disorders. Thromb Haemost 1991; 65:237-41.
3. Sramek A, Eikenboom JC, Briet E, Vandenbroucke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch Int Med 1995; 155:1409-15.
4. Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101:2089-93.
5. Rao AK. Inherited defects in platelet signaling mechanisms. J Thromb Haemost 2003; 1:671-81.
6. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003; 1:1628-36.
7. Hayward CPM. Inherited platelet disorders. Curr Opin Hematol 2003; 10:362-8.
8. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000; 111:733-44.
9. Moffat KA, Ledford-Kraemer MR, Nichols WL, Hayward CPM. Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North America Specialized Coagulation Laboratory Association. Thromb Haemost 2005; 93:549-53.
10. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104:1243-52.
11. Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339:245-53.
12. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999; 57:1005-32.
13. Quiroga T, Goycoolea M, Muñoz B, Morales M, Aranda E, Panes O, et al. Template bleeding time and PFA-100® have low sensitivity to screen patients with mucocutaneous haemorrhages of hereditary nature: comparative study in 148 patients. J Thromb Haemost 2004; 2:892-8.
14. Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost 2003; 90:483-90.
15. Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor XI-deficiency kindreds - a clinical and laboratory study. Thromb Haemost 1995; 73:194-202.
16. Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests. J Lab Clin Med 1953; 41:637-47.
17. Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980; 302:1047-51.
18. Jorieux S, Fressinaud E, Goudemand J, Gaucher C, Meyer D, Mazurier C. Conformational changes in the D′ domain of von Willebrand factor induced by CYS 25 and CYS 95 mutations lead to factor VIII binding defect and multimeric impairment. Blood 2000; 95:3139-45.
19. Sadler E, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84:160-74.
20. Sadler JE. Slippery criteria for von Willebrand's disease type 1. J Thromb Haemost 2004; 2:1720-23.
21. Kumar AM, Kumar M, Deepika K, Fernandez JB, Eisdorfer C. A modified HPLC technique for simultaneous measurement of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in cerebrospinal fluid, platelet and plasma. Life Sci 1990; 47:1751-9.
22. Holmsen H, Dangelmaier CA. Measurement of secretion of adenine nucleotides. In: Hawiger J, ed. Methods in Enzymology, San Diego, CA: Academic Press; 169; 1989:195-205.
23. von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86:3035-42.
24. Cattaneo M. Are the bleeding time and PFA-100 useful in the initial screening of patients with mucocutaneous bleedings of hereditary nature? J Thromb Haemost 2004; 2:890-1.
25. Gill C J, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69:1691-5.
26. Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ. Type 1 von Willebrand disease - a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 2000; 108:259-64.
27. Rodeghiero F. von Willebrand disease: still an intriguing disorder in the era of molecular medicine. Haemophilia 2002; 8:292-300.
28. Valenzuela CY, Acuña MP, Harb Z. A socio-genetic cline in Chilean population. Rev Med Chile 1987; 115:295-9.
29. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4:766-73.
30. Breddin HK. Can platelet aggregometry be standardized? Platelets 2005; 16:151-8.
31. Weiss HJ, Witte LD, Kaplan KL, Lages BA, Chernoff A, Nossel HL, et al. Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in α-granules, platelet factor 4, β-thromboglobulin, and platelet-derived growth factor. Blood 1979; 54:1296-319.
32. Tyrer SP, Marshall EF, Griffiths HW. The relationship between response to fluoxetine, plasma drug levels, Imipramine binding to platelet membranes and whole-blood 5-HT. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14:797-805.
33. Nieuwenhuis HK, Akkerman J-WN, Sixma JJ. Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood 1987; 70:620-3.
34. Israels SJ, McNicol A, Robertson C, Gerrard JM. Platelet storage pool deficiency: diagnosis in patients with prolonged bleeding times and normal platelet aggregation. Br J Haematol 1990; 75:118-21.
35. Wuillemin WA, Gasser KM, Zeerleder SS, Lammle B. Evaluation of a platelet function analyzer (PFA-100®) in patients with a bleeding tendency. Swiss Med Wkly 2002; 132:443-8.
36. Sandoval C, Dong S, Visintainer P, et al. Clinical and laboratory features of 178 children with recurrent epistaxis. J Ped Hematol-Oncol 2002; 24:47-9.
37. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351:485-9.
38. Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342:374-80.
39. Gerrard JM, Duta E, Nosek-Cenkowska B, Singhroy S, Cheang M, Kobrinsky NL. A role for prostacyclin in bruising symptomatology. Pediatrics 1992; 90:33-6.
40. Simon DI, Stamler JS, Loh E, Loscalzo J, Francis SA, Creager MA. Effects of nitric oxide synthase inhibition on bleeding time in humans. J Cardiovasc Pharmacol 1995; 26:339-42.
41. Ubatuba FB, Moncada S, Vane JR. The effect of prostacyclin (PGI2) on platelet behaviour. Thrombus formation in vivo and bleeding time. Thromb Haemost 1979; 23:425-35.